Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACC-001 Clear all
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 (vanutide cridificar)
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 11, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

NCT01227564
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 11, 2026, 10:05 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00960531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Sep 11, 2026, 10:05 AM EDT